Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity.

Int J Cancer · 2026 · PMC13193497 · PMID 41787605

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

25 Our data show a nonsignificant trend indicating some tamoxifen benefit also for patients with ER‐positive and PR‐negative disease.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.